New York, New York–(Newsfile Corp. – January 20, 2025) – WHY: The Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX ) between August 2, 2023 and August 8, 2024, both dates inclusive (“Teaching Period”). A lawsuit has already been filed. If you want to be the chief prosecutor, you have to move the court no later than March 14, 2025.
SO WHAT: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without paying any fees or out-of-pocket expenses through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Pacira class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=33570 or call Phillip Kim, Esq. toll free at 866-767-3653 or email case@rosenlegal.com for information about the class action. A class action lawsuit has already been filed. If you want to be the chief prosecutor, you have to move the court no later than March 14, 2025. The lead plaintiff is the representative party that acts on behalf of the other class members in the conduct of the litigation.
WHY ROSEN’S LAW: We encourage investors to choose a qualified advisor with experience in successful leadership roles. Often the firms issuing the notices do not have comparable experience, resources or any significant recognition from their peers. Be wise in choosing an advisor. The Rosen Law Firm represents investors worldwide, concentrating its practice in securities class actions and equity derivative litigation. The Rosen Law Firm secured the largest securities class action settlement to date against a Chinese company at the time. The Rosen Law Firm is ranked #1 by ISS Securities Class Action (WA:) Services for numerous securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company secured more than $438 million for investors. In 2020, founding partner Laurence Rosen was named a Law360 Claimant Bar Association Titan. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.
CASE DETAILS: According to the lawsuit, the statements made during the Class Period were false and/or misleading because the defendants created the false impression that Pacira had sufficient patent protection on Exparel and, as such, the ability to expand the marketing, manufacturing and sales of Exparel, which Pacira said is key to its future growth and revenues. True, Pacira’s optimistic claims regarding its patent protection on Exparel were tenuous at best. In fact, Pacira knew that the ‘495 patent was not as protective as the defendants publicly touted because on June 6, 2023, a New Jersey district court ruled in favor of eVenus on claim construction in another case filed by Pacira in an unsuccessful attempt Exparel protection. Nevertheless, the defendants continued to make public statements asserting their belief in the ‘495 patent and the protection it applied to Exparel. When the true details came to market, the lawsuit alleges, investors suffered damages.
To join the Pacira class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=33570 or call Phillip Kim, Esq. toll free at 866-767-3653 or email case@rosenlegal.com for information about the class action.
No class is certified. Until the class is certified, you will not be represented by an attorney unless you retain one. You can choose a lawyer of your choice. You can also remain an absent member of the class and do nothing at this time. An investor’s ability to participate in a potential future recovery does not depend on whether it is the lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https:/ /www.facebook.com/rosenlawfirm.
Advertising of lawyers. Previous results do not guarantee a similar outcome.
——————————–
To view the original version of this press release, please visit https://www.newsfilecorp.com/release/237816
